Business Context and Reporting Period
This Form 8-K is a current report filed by Aziyo Biologics, Inc. (trading symbol: AZYO) on February 24, 2021. The registrant is an emerging growth company incorporated in Delaware. The filing addresses Item 5.02 regarding the approval of the 2020 annual cash bonus plan for executive officers following the completion of the company's initial public offering (IPO).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue totals, profit margins, cash flow, debt, or liquidity metrics. The only specific financial figures disclosed relate to executive compensation:
- 2020 Revenue Target: At least $39,168,000 (confirmed as exceeded).
- Total 2020 Bonus Pool Approved: $1,546,198 (100% of the target pool).
- Individual Executive Bonuses:
- Ronald Lloyd (CEO): $392,381
- Matthew Ferguson (CFO): $40,993
- Darryl Roberts: $152,955
- Thomas Englese: $162,717
Material Changes
The primary material event reported is the determination by the Compensation Committee that the company met or exceeded its 2020 performance goals. Specifically, the company confirmed the completion of its IPO and the achievement of revenue targets exceeding $39,168,000. Consequently, the full target bonus pool was authorized for distribution.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies. The document is strictly limited to the administrative approval of the 2020 bonus plan based on past performance metrics.
Investor Verification Checklist
- Verify the actual 2020 revenue figures in the company's most recent 10-K or 10-Q to confirm the extent to which the $39,168,000 target was exceeded.
- Review the final IPO prospectus to confirm the total number of shares issued and the capital raised, as this filing references the IPO completion as a key performance metric.
- Check subsequent filings for the actual disbursement of the approved $1,546,198 bonus pool.
- Confirm the current status of the company's clinical development and commercial achievement goals mentioned as qualitative performance criteria.